CB1

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
MUC, Human, Biotechnology, CSPC, Drug discovery, Carcinoma, Cervical cancer, Rash, Patient, MMAE, Tumor microenvironment, Peripheral neuropathy, IND, PH1b, Insulin resistance, Investment, Investigational New Drug, Therapy, CB1, ATM, Safety, Liraglutide, CMO, FDA, PD-1, Pharmaceutical industry

We expect to dose the first patient in our US Ph1 study in March 2024.

Key Points: 
  • We expect to dose the first patient in our US Ph1 study in March 2024.
  • For CRB-601, the FDA cleared our Investigational New Drug (“IND”) application in January 2024, and we expect to dose the first patient this summer.
  • The Company presented CRB-913 pre-clinical data at Obesity Week as an oral presentation and as a late breaking poster in October 2023.
  • The Company is currently conducting IND enabling studies and expects to file an IND in the fourth quarter of 2024.

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024
Therapy, AstraZeneca, CMO, CD25, Biotechnology, Roche, Neoplasm, Physician, Obesity, Amgen, Icon, Pharmaceutical medicine, Bladder cancer, Royal college, ADC, Antibody, NHS, Safety, CB1, CSPC, Patient, CD137, Faculty, Partnership, Pharmaceutical industry

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).

Key Points: 
  • NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).
  • Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company’s highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
  • “We are pleased to welcome Dominic to the Corbus team and look forward to benefitting from his experience in developing novel oncology therapeutics including ones that specifically target Nectin-4", said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Previously, Dr. Smethurst worked as a consultant advising biopharma companies, providing guidance on clinical development strategies and licensing projects.

Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Retrieved on: 
Monday, February 26, 2024
OTCQB, SAN, IOP, Glaucoma, OE, Blood, Obesity, OHT, Eye, Database, Safety, Biomarker, CB1, Ocular hypertension, Patient, THC, Hyperaemia, Trial of the century, Isle of Skye, Pharmaceutical industry

All treated patients completed the study, with no early discontinuations due to adverse events.

Key Points: 
  • All treated patients completed the study, with no early discontinuations due to adverse events.
  • “Because this trial completed enrollment ahead of schedule, our initially intended interim data report based on partial enrollment is unnecessary.
  • Skye is evaluating SBI-100 OE’s ability to lower IOP, safety and relevant biomarkers in patients with POAG or OHT.
  • Low rate of hyperaemia (red eyes) of 8.4% compared to higher rates in other leading classes of glaucoma drugs.

High-Not: a THC Recovery shot to "Ease Your High."

Retrieved on: 
Wednesday, February 21, 2024
Cannabis, Retail, Health, Tobacco, Natural Resources, Specialty, General Health, FDA, Good, Smoking, Limonene, Electrolyte, CB2, Disease, Terpene, Nursing, CB1, GMP, Absorption, THC

Enter High-Not, the groundbreaking recovery shot that empowers consumers to control their cannabis experience.

Key Points: 
  • Enter High-Not, the groundbreaking recovery shot that empowers consumers to control their cannabis experience.
  • Crafted in a state-of-the-art GMP (Good Manufacturing Practice) facility, High-Not’s ingredients include limonene, black pepper extract, L-theanine, and electrolytes.
  • This unique, cannabis-free mix offers a safe and reliable solution for consumers seeking to mitigate the effects of THC.
  • High-Not is not guaranteed to work with everyone or alleviate every side effect of THC.

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

Retrieved on: 
Monday, January 29, 2024
Obesity, OE, Patient, PIPE, Richard Driehaus, Leptin, Fasting, Visium Asset Management, Sale, Ocular hypertension, OTCQB, Exchange, CB1, Safety, Triglyceride, Netarsudil, Glaucoma, Waist, Cholesterol, Security (finance), Body composition, Oppenheimer Holdings, Pharmaceutical industry

Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination with a GLP-1R agonist

Key Points: 
  • Gross proceeds from the PIPE are expected to be $50.25 million, before deducting any placement agent fees and offering-related expenses.
  • The PIPE financing is expected to close on January 31, 2024, subject to the satisfaction of customary closing conditions.
  • The PIPE financing was co-led by a life sciences-focused investor and 5AM Ventures, with participation from Ally Bridge Group, Sphera Healthcare, Altium Capital, Driehaus Capital Management and other institutional investors.
  • Piper Sandler is acting as the lead placement agent and Oppenheimer & Co. is acting as a placement agent for the PIPE financing.

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s

Retrieved on: 
Tuesday, January 23, 2024
Research, Technology, Other Technology, Clinical Trials, Other Health, Managed Care, General Health, Pharmaceutical, Health, Science, Pathology, Dementia, Plaque, Alzheimer's disease, Neuron, Lecanemab, CB1, Disease, FDA, Agitation, Aducanumab, Brain, IGC, Neurodegenerative disease

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) provides details on its drug candidate TGR-63, which targets amyloid-beta plaque and can potentially improve Alzheimer's disease treatment in a significant manner.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) provides details on its drug candidate TGR-63, which targets amyloid-beta plaque and can potentially improve Alzheimer's disease treatment in a significant manner.
  • TGR-63 is a patent pending molecule designed to disrupt the structure of Aβ plaque aggregation by disrupting intermolecular interactions and destabilizing their assembly.
  • As a result, large clusters of plaque fail to form, potentially stifling the progression of Alzheimer's Disease.
  • This trial spans twelve sites across the U.S. and Canada, with data milestones based on patient recruitment efficiency anticipated in the second half of 2024.

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial

Retrieved on: 
Wednesday, January 17, 2024
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Patient, Dementia, Partnership, Data collection, Alzheimer's disease, CB1, Caregiver, Agitation, IGC, Pharmaceutical industry

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that ClinCloud, a clinical research facility in Florida, has dosed its first patient as part of the Company’s ongoing Phase 2b trial.

Key Points: 
  • IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that ClinCloud, a clinical research facility in Florida, has dosed its first patient as part of the Company’s ongoing Phase 2b trial.
  • IGC Pharma is currently conducting a Phase 2b trial at twelve sites in the US and Canada with IGC-AD1, a combination medicine with a CB1 receptor partial agonist with anti-neuroinflammatory properties, and an inflammasome inhibitor to treat agitation in dementia from Alzheimer’s.
  • Individuals diagnosed with Alzheimer’s disease and/or their caregivers who live near the sites are encouraged to contact ClinCloud for information regarding enrolling in the trial.
  • We’re glad to support this Phase 2b clinical trial as it aligns with ClinCloud’s goal of transforming healthcare with continuous improvements and revolutionary breakthroughs.

Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Retrieved on: 
Monday, December 11, 2023
GIP, NAFLD, Traffic barrier, Cholesterol, Food, Șaeș, IND, Non-alcoholic fatty liver disease, Drug discovery, FDA, Kidney disease, Weight loss, Syringe, Trial of the century, Half-life, Obesity, Investigational New Drug, Chronic kidney disease, OTCQB, CNS, CB1, Biomarker, Prediabetes, Central nervous system, Patient, Safety, Albuminuria, Pharmaceutical industry

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system, announced today that it plans to develop nimacimab, the Company’s monoclonal antibody recently acquired from Bird Rock Bio, for weight loss and the treatment of obesity. The Company has filed an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for the initiation of a Phase 2 clinical study of nimacimab in patients with obesity and chronic kidney disease.

Key Points: 
  • Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 receptor ("CB1"), which has been implicated as an important target in multiple cardiometabolic diseases including obesity and renal complications.
  • Obesity and kidney disease are highly correlated: 80% of patients who have kidney disease are also obese; 30% of obese patients have kidney disease.
  • Nimacimab effectively inhibits CB1 signaling and, based on preclinical and early clinical studies, is devoid of the CNS liabilities typically seen by small molecule drugs that target the CB1 receptor because it does not cross the blood-brain barrier.
  • Skye owns the worldwide rights to nimacimab, with patents issued in the U.S. and other territories including claims to cannabinoid 1 receptor antibodies with inverse agonist function.

Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion

Retrieved on: 
Tuesday, November 28, 2023
IOP, Patient, Hyperaemia, Risk, Trial of the century, Blood, MD, SAN, THC, Eye, Isle of Skye, Intraocular pressure, OHT, Ocular hypertension, OTCQB, CB1, Biomarker, OE, Safety, Non-Euclidean geometry, Glaucoma, Pharmaceutical industry

SBI-100 OE is a synthetic prodrug of tetrahydrocannabinol (“THC”) that is able to bind and activate CB1 receptors in key ocular tissues.

Key Points: 
  • SBI-100 OE is a synthetic prodrug of tetrahydrocannabinol (“THC”) that is able to bind and activate CB1 receptors in key ocular tissues.
  • We are advancing the next generation of investigational drugs targeting the endocannabinoid system’s CB1 receptor,” said Punit Dhillon, Skye’s CEO and Chairman.
  • “This Phase 2 study provides an avenue to confirm IOP-lowering ability and advance the potential for SBI-100 OE in treating ophthalmic disorders.
  • In preclinical studies involving three different species, SBI-100 OE lowered IOP to a level and duration that compared favorably to the standard of care for treating glaucoma.

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s

Retrieved on: 
Tuesday, December 19, 2023
Research, General Health, Cannabis, Pharmaceutical, Mental Health, Technology, Natural Resources, Artificial Intelligence, Health Technology, Clinical Trials, Science, Neurology, Health, Quality of life, Alzheimer's disease, Agitation, Caregiver, Caregiver burden, Composition, Patent, Treating, Public, CNS, Disorder, LMP, CB1, Somatic symptom disorder, Patient, IGC, Central nervous system, Pharmaceutical industry

IGC Pharma is currently progressing a Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer’s disease, the most common form of a central nervous system disorder (CNS).

Key Points: 
  • IGC Pharma is currently progressing a Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer’s disease, the most common form of a central nervous system disorder (CNS).
  • IGC Pharma has strategically sought patent protection for the IGC-AD1 formulation in many jurisdictions including the U.S., Europe, Canada, and Mexico.
  • Today’s announcement of the issuance of the patent for the drug formulation that targets Central Nervous System (CNS) Disorders marks an important milestone in helping set the stage for potential commercialization.
  • IGC Pharma is currently pursuing five drug assets targeting the treatment of agitation related to symptoms of Alzheimer's disease.